Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 12 March, 2025
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo
Stock Ticker - BSE: | NSE:

Sakar Healthcare Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: March 8, 2025, 10:56 am

Market Cap 585 Cr.
Current Price 267
High / Low 408/213
Stock P/E39.3
Book Value 123
Dividend Yield0.00 %
ROCE7.31 %
ROE5.28 %
Face Value 10.0
PEG Ratio-447.23

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Sakar Healthcare Ltd

Competitors of Sakar Healthcare Ltd

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
NG Industries Ltd 57.0 Cr. 170 206/1364.70 1242.06 %6.50 %5.63 % 10.0
Global Longlife Hospital and Research Ltd 25.5 Cr. 24.2 46.4/22.1 25.90.00 %2.51 %4.72 % 10.0
Gian Lifecare Ltd 18.1 Cr. 17.5 29.0/12.14.43 19.20.00 %29.2 %24.6 % 10.0
Fortis Malar Hospitals Ltd 118 Cr. 62.7 108/44.0153 15.967.8 %3.29 %9.12 % 10.0
Family Care Hospitals Ltd 26.7 Cr. 4.95 9.50/4.320.70 2.670.00 %15.4 %24.1 % 10.0
Industry Average22,314.27 Cr670.2353.4489.393.10%12.34%12.42%9.12

All Competitor Stocks of Sakar Healthcare Ltd

Quarterly Result

MetricDec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Sales 29.7436.5928.5330.7133.4740.6538.9934.0837.2343.0641.1542.7843.42
Expenses 23.0927.4120.5722.1224.6732.8729.9624.7228.2232.0930.4531.2831.66
Operating Profit 6.659.187.968.598.807.789.039.369.0110.9710.7011.5011.76
OPM % 22.36%25.09%27.90%27.97%26.29%19.14%23.16%27.46%24.20%25.48%26.00%26.88%27.08%
Other Income 0.270.880.410.601.851.811.520.660.230.770.460.370.25
Interest 0.940.680.860.991.942.152.081.651.792.081.401.641.30
Depreciation 2.623.193.573.774.103.554.524.224.444.875.065.125.23
Profit before tax 3.366.193.944.434.613.893.954.153.014.794.705.115.48
Tax % 96.43%-45.56%26.90%56.21%13.02%-0.77%28.10%12.53%30.90%34.86%48.72%6.07%17.15%
Net Profit 0.119.012.881.944.013.922.843.642.073.122.414.804.53
EPS in Rs 0.065.261.681.042.152.061.491.700.951.431.112.212.06

Last Updated: February 28, 2025, 5:23 pm

Below is a detailed analysis of the quarterly data for Sakar Healthcare Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

  • For Sales, as of Dec 2024, the value is ₹43.42 Cr.. The value appears strong and on an upward trend. It has increased from 42.78 Cr. (Sep 2024) to ₹43.42 Cr., marking an increase of ₹0.64 Cr..
  • For Expenses, as of Dec 2024, the value is ₹31.66 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 31.28 Cr. (Sep 2024) to ₹31.66 Cr., marking an increase of ₹0.38 Cr..
  • For Operating Profit, as of Dec 2024, the value is ₹11.76 Cr.. The value appears strong and on an upward trend. It has increased from 11.50 Cr. (Sep 2024) to ₹11.76 Cr., marking an increase of ₹0.26 Cr..
  • For OPM %, as of Dec 2024, the value is 27.08%. The value appears strong and on an upward trend. It has increased from 26.88% (Sep 2024) to 27.08%, marking an increase of 0.20%.
  • For Other Income, as of Dec 2024, the value is ₹0.25 Cr.. The value appears to be declining and may need further review. It has decreased from 0.37 Cr. (Sep 2024) to ₹0.25 Cr., marking a decrease of 0.12 Cr..
  • For Interest, as of Dec 2024, the value is ₹1.30 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.64 Cr. (Sep 2024) to ₹1.30 Cr., marking a decrease of 0.34 Cr..
  • For Depreciation, as of Dec 2024, the value is ₹5.23 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.12 Cr. (Sep 2024) to ₹5.23 Cr., marking an increase of ₹0.11 Cr..
  • For Profit before tax, as of Dec 2024, the value is ₹5.48 Cr.. The value appears strong and on an upward trend. It has increased from 5.11 Cr. (Sep 2024) to ₹5.48 Cr., marking an increase of ₹0.37 Cr..
  • For Tax %, as of Dec 2024, the value is 17.15%. The value appears to be increasing, which may not be favorable. It has increased from 6.07% (Sep 2024) to 17.15%, marking an increase of 11.08%.
  • For Net Profit, as of Dec 2024, the value is ₹4.53 Cr.. The value appears to be declining and may need further review. It has decreased from 4.80 Cr. (Sep 2024) to ₹4.53 Cr., marking a decrease of 0.27 Cr..
  • For EPS in Rs, as of Dec 2024, the value is 2.06. The value appears to be declining and may need further review. It has decreased from ₹2.21 (Sep 2024) to 2.06, marking a decrease of ₹0.15.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 2:59 pm

MetricMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024TTM
Sales 223035414453688395128133153170
Expenses 14222733344051637299100115125
Operating Profit 8888101317202329333845
OPM % 34%26%22%20%23%24%25%24%24%23%25%25%26%
Other Income 0000101212532
Interest 4433332223686
Depreciation 22233467810151820
Profit before tax 2223569121319171620
Tax % 19%13%24%22%30%38%28%21%19%20%24%27%
Net Profit 1222347101115131215
EPS in Rs 1.812.192.302.783.083.124.476.436.848.906.705.376.81
Dividend Payout % 0%0%0%0%0%0%0%0%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)100.00%0.00%0.00%50.00%33.33%75.00%42.86%10.00%36.36%-13.33%-7.69%
Change in YoY Net Profit Growth (%)0.00%-100.00%0.00%50.00%-16.67%41.67%-32.14%-32.86%26.36%-49.70%5.64%

Sakar Healthcare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:18%
5 Years:18%
3 Years:17%
TTM:13%
Compounded Profit Growth
10 Years:21%
5 Years:11%
3 Years:2%
TTM:19%
Stock Price CAGR
10 Years:%
5 Years:33%
3 Years:28%
1 Year:-34%
Return on Equity
10 Years:10%
5 Years:9%
3 Years:8%
Last Year:5%

Last Updated: Unknown

Balance Sheet

Last Updated: December 14, 2024, 2:50 pm

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital 8888111215151617192222
Reserves 467112539576683110154241248
Borrowings 272425222411111743931197974
Other Liabilities 11141110111815173747444761
Total Liabilities 50525051718197115178268336389404
Fixed Assets 373836374953646669205267314317
CWIP 000000913491601
Investments 0000000007300
Other Assets 13141414222825366055607487
Total Assets 50525051718197115178268336389404

Below is a detailed analysis of the balance sheet data for Sakar Healthcare Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2024, the value is ₹22.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹22.00 Cr..
  • For Reserves, as of Sep 2024, the value is ₹248.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹241.00 Cr. (Mar 2024) to ₹248.00 Cr., marking an increase of 7.00 Cr..
  • For Borrowings, as of Sep 2024, the value is ₹74.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from ₹79.00 Cr. (Mar 2024) to ₹74.00 Cr., marking a decrease of 5.00 Cr..
  • For Other Liabilities, as of Sep 2024, the value is ₹61.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹47.00 Cr. (Mar 2024) to ₹61.00 Cr., marking an increase of 14.00 Cr..
  • For Total Liabilities, as of Sep 2024, the value is ₹404.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹389.00 Cr. (Mar 2024) to ₹404.00 Cr., marking an increase of 15.00 Cr..
  • For Fixed Assets, as of Sep 2024, the value is ₹317.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹314.00 Cr. (Mar 2024) to ₹317.00 Cr., marking an increase of 3.00 Cr..
  • For CWIP, as of Sep 2024, the value is ₹1.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹0.00 Cr. (Mar 2024) to ₹1.00 Cr., marking an increase of 1.00 Cr..
  • For Investments, as of Sep 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹0.00 Cr..
  • For Other Assets, as of Sep 2024, the value is ₹87.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹74.00 Cr. (Mar 2024) to ₹87.00 Cr., marking an increase of 13.00 Cr..
  • For Total Assets, as of Sep 2024, the value is ₹404.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹389.00 Cr. (Mar 2024) to ₹404.00 Cr., marking an increase of 15.00 Cr..

Notably, the Reserves (₹248.00 Cr.) exceed the Borrowings (74.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity +794925161915363324
Cash from Investing Activity +-3-3-1-4-14-8-25-22-47-90-74-52
Cash from Financing Activity +-7-6-3-613-139332554127
Net Cash Flow-4-01-10-160-0-0-000

Free Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow-19.00-16.00-17.00-14.00-14.002.006.003.00-20.00-64.00-86.00-41.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days222821264474513648406050
Inventory Days2811901421071145170921126976121
Days Payable10997206651574146141149129120
Cash Conversion Cycle1941201436710768808319-39751
Working Capital Days1557589451101084641823062
ROCE %14%15%14%14%15%14%16%16%13%12%9%7%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Promoters67.54%67.54%62.10%62.10%60.72%60.72%54.15%53.15%53.15%53.15%53.15%53.58%
FIIs0.00%0.00%16.12%16.12%15.74%15.74%14.03%13.76%13.52%13.52%13.42%13.58%
DIIs8.76%8.76%0.55%0.33%0.00%0.00%10.82%10.62%10.62%10.62%10.62%10.88%
Public23.70%23.70%21.24%21.45%23.54%23.54%21.00%22.47%22.71%22.71%22.80%21.96%
No. of Shareholders6,7026,0915,6786,2106,3226,0567,2997,0017,3867,3137,8678,598

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 5.636.758.736.846.43
Diluted EPS (Rs.) 5.636.758.736.846.43
Cash EPS (Rs.) 13.6614.5714.5212.0011.16
Book Value[Excl.RevalReserv]/Share (Rs.) 120.6191.0474.4663.0454.35
Book Value[Incl.RevalReserv]/Share (Rs.) 120.6191.0474.4663.0454.35
Revenue From Operations / Share (Rs.) 70.5170.0474.9160.6655.46
PBDIT / Share (Rs.) 19.1019.8618.4015.2214.41
PBIT / Share (Rs.) 10.8011.9912.7510.069.68
PBT / Share (Rs.) 7.318.8711.068.478.17
Net Profit / Share (Rs.) 5.376.708.876.846.43
NP After MI And SOA / Share (Rs.) 5.376.708.876.846.43
PBDIT Margin (%) 27.0828.3524.5625.0925.98
PBIT Margin (%) 15.3117.1117.0216.5817.44
PBT Margin (%) 10.3612.6514.7613.9614.73
Net Profit Margin (%) 7.619.5611.8311.2711.59
NP After MI And SOA Margin (%) 7.619.5611.8311.2711.59
Return on Networth / Equity (%) 4.447.3611.9010.8511.83
Return on Capital Employeed (%) 7.128.109.8710.8714.35
Return On Assets (%) 3.003.795.666.008.36
Long Term Debt / Equity (X) 0.200.560.660.390.15
Total Debt / Equity (X) 0.260.640.700.400.18
Asset Turnover Ratio (%) 0.420.440.570.640.00
Current Ratio (X) 1.211.031.071.011.52
Quick Ratio (X) 0.740.740.760.540.75
Interest Coverage Ratio (X) 5.476.3610.879.589.57
Interest Coverage Ratio (Post Tax) (X) 2.543.156.245.305.27
Enterprise Value (Cr.) 869.42493.09320.85216.7089.08
EV / Net Operating Revenue (X) 5.673.702.502.291.07
EV / EBITDA (X) 20.9313.0410.199.124.13
MarketCap / Net Operating Revenue (X) 5.222.861.801.860.90
Price / BV (X) 3.052.201.811.790.91
Price / Net Operating Revenue (X) 5.222.861.801.860.90
EarningsYield 0.010.030.060.060.12

After reviewing the key financial ratios for Sakar Healthcare Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
  • For Basic EPS (Rs.), as of Mar 24, the value is 5.63. This value is within the healthy range. It has decreased from 6.75 (Mar 23) to 5.63, marking a decrease of 1.12.
  • For Diluted EPS (Rs.), as of Mar 24, the value is 5.63. This value is within the healthy range. It has decreased from 6.75 (Mar 23) to 5.63, marking a decrease of 1.12.
  • For Cash EPS (Rs.), as of Mar 24, the value is 13.66. This value is within the healthy range. It has decreased from 14.57 (Mar 23) to 13.66, marking a decrease of 0.91.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 120.61. It has increased from 91.04 (Mar 23) to 120.61, marking an increase of 29.57.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 120.61. It has increased from 91.04 (Mar 23) to 120.61, marking an increase of 29.57.
  • For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 70.51. It has increased from 70.04 (Mar 23) to 70.51, marking an increase of 0.47.
  • For PBDIT / Share (Rs.), as of Mar 24, the value is 19.10. This value is within the healthy range. It has decreased from 19.86 (Mar 23) to 19.10, marking a decrease of 0.76.
  • For PBIT / Share (Rs.), as of Mar 24, the value is 10.80. This value is within the healthy range. It has decreased from 11.99 (Mar 23) to 10.80, marking a decrease of 1.19.
  • For PBT / Share (Rs.), as of Mar 24, the value is 7.31. This value is within the healthy range. It has decreased from 8.87 (Mar 23) to 7.31, marking a decrease of 1.56.
  • For Net Profit / Share (Rs.), as of Mar 24, the value is 5.37. This value is within the healthy range. It has decreased from 6.70 (Mar 23) to 5.37, marking a decrease of 1.33.
  • For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 5.37. This value is within the healthy range. It has decreased from 6.70 (Mar 23) to 5.37, marking a decrease of 1.33.
  • For PBDIT Margin (%), as of Mar 24, the value is 27.08. This value is within the healthy range. It has decreased from 28.35 (Mar 23) to 27.08, marking a decrease of 1.27.
  • For PBIT Margin (%), as of Mar 24, the value is 15.31. This value is within the healthy range. It has decreased from 17.11 (Mar 23) to 15.31, marking a decrease of 1.80.
  • For PBT Margin (%), as of Mar 24, the value is 10.36. This value is within the healthy range. It has decreased from 12.65 (Mar 23) to 10.36, marking a decrease of 2.29.
  • For Net Profit Margin (%), as of Mar 24, the value is 7.61. This value is within the healthy range. It has decreased from 9.56 (Mar 23) to 7.61, marking a decrease of 1.95.
  • For NP After MI And SOA Margin (%), as of Mar 24, the value is 7.61. This value is below the healthy minimum of 8. It has decreased from 9.56 (Mar 23) to 7.61, marking a decrease of 1.95.
  • For Return on Networth / Equity (%), as of Mar 24, the value is 4.44. This value is below the healthy minimum of 15. It has decreased from 7.36 (Mar 23) to 4.44, marking a decrease of 2.92.
  • For Return on Capital Employeed (%), as of Mar 24, the value is 7.12. This value is below the healthy minimum of 10. It has decreased from 8.10 (Mar 23) to 7.12, marking a decrease of 0.98.
  • For Return On Assets (%), as of Mar 24, the value is 3.00. This value is below the healthy minimum of 5. It has decreased from 3.79 (Mar 23) to 3.00, marking a decrease of 0.79.
  • For Long Term Debt / Equity (X), as of Mar 24, the value is 0.20. This value is within the healthy range. It has decreased from 0.56 (Mar 23) to 0.20, marking a decrease of 0.36.
  • For Total Debt / Equity (X), as of Mar 24, the value is 0.26. This value is within the healthy range. It has decreased from 0.64 (Mar 23) to 0.26, marking a decrease of 0.38.
  • For Asset Turnover Ratio (%), as of Mar 24, the value is 0.42. It has decreased from 0.44 (Mar 23) to 0.42, marking a decrease of 0.02.
  • For Current Ratio (X), as of Mar 24, the value is 1.21. This value is below the healthy minimum of 1.5. It has increased from 1.03 (Mar 23) to 1.21, marking an increase of 0.18.
  • For Quick Ratio (X), as of Mar 24, the value is 0.74. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 23) which recorded 0.74.
  • For Interest Coverage Ratio (X), as of Mar 24, the value is 5.47. This value is within the healthy range. It has decreased from 6.36 (Mar 23) to 5.47, marking a decrease of 0.89.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 2.54. This value is below the healthy minimum of 3. It has decreased from 3.15 (Mar 23) to 2.54, marking a decrease of 0.61.
  • For Enterprise Value (Cr.), as of Mar 24, the value is 869.42. It has increased from 493.09 (Mar 23) to 869.42, marking an increase of 376.33.
  • For EV / Net Operating Revenue (X), as of Mar 24, the value is 5.67. This value exceeds the healthy maximum of 3. It has increased from 3.70 (Mar 23) to 5.67, marking an increase of 1.97.
  • For EV / EBITDA (X), as of Mar 24, the value is 20.93. This value exceeds the healthy maximum of 15. It has increased from 13.04 (Mar 23) to 20.93, marking an increase of 7.89.
  • For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 5.22. This value exceeds the healthy maximum of 3. It has increased from 2.86 (Mar 23) to 5.22, marking an increase of 2.36.
  • For Price / BV (X), as of Mar 24, the value is 3.05. This value exceeds the healthy maximum of 3. It has increased from 2.20 (Mar 23) to 3.05, marking an increase of 0.85.
  • For Price / Net Operating Revenue (X), as of Mar 24, the value is 5.22. This value exceeds the healthy maximum of 3. It has increased from 2.86 (Mar 23) to 5.22, marking an increase of 2.36.
  • For EarningsYield, as of Mar 24, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 23) to 0.01, marking a decrease of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Sakar Healthcare Ltd as of March 12, 2025 is: ₹208.27

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 12, 2025, Sakar Healthcare Ltd is Overvalued by 22.00% compared to the current share price 267.00

Intrinsic Value of Sakar Healthcare Ltd as of March 12, 2025 is: 208.09

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 12, 2025, Sakar Healthcare Ltd is Overvalued by 22.06% compared to the current share price 267.00

Last 5 Year EPS CAGR: -0.09%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The company has higher reserves (80.85 cr) compared to borrowings (43.77 cr), indicating strong financial stability.
  2. The company has shown consistent growth in sales (81.15 cr) and profit (9.69 cr) over the years.
  1. The stock has a low average ROCE of 13.25%, which may not be favorable.
  2. The stock has a high average Working Capital Days of 64.25, which may not be favorable.
  3. The stock has a high average Cash Conversion Cycle of 75.00, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Sakar Healthcare Ltd:
    1. Net Profit Margin: 7.61%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 7.12% (Industry Average ROCE: 12.34%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 4.44% (Industry Average ROE: 12.42%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 2.54
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 0.74
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 39.3 (Industry average Stock P/E: 53.44)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.26
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Sakar Healthcare Ltd. is a Public Limited Listed company incorporated on 26/03/2004 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24231GJ2004PLC043861 and registration number is 043861. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 153.35 Cr. and Equity Capital is Rs. 21.75 Cr. for the Year ended 31/03/2024.
INDUSTRYADDRESSCONTACT
Hospitals & Medical ServicesBlock No. 10/13, Village: Changodar, Ahmedabad District Gujarat 382213cs@sakarhealthcare.com
http://www.sakarhealthcare.com
Management
NamePosition Held
Mr. Sanjay S ShahChairman & Managing Director
Mr. Aarsh S ShahJoint Managing Director
Mr. Sunil MaratheWhole Time Director - Technical
Ms. Vishalakshi ChandramouliNon Executive Director
Ms. Rita S ShahNon Executive Director
Mr. Hemendra C ShahIndependent Director
Mr. Shailesh B PatelIndependent Director
Mr. Prashant C SrivastavIndependent Director
Mr. Jignesh ParikhIndependent Director
Mrs. Khyati ShahIndependent Director

FAQ

What is the latest intrinsic value of Sakar Healthcare Ltd?

The latest intrinsic value of Sakar Healthcare Ltd as on 09 March 2025 is ₹208.27, which is 22.00% lower than the current market price of 267.00, indicating the stock is overvalued by 22.00%. The intrinsic value of Sakar Healthcare Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹585 Cr. and recorded a high/low of ₹408/213 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹248 Cr and total liabilities of ₹404 Cr.

What is the Market Cap of Sakar Healthcare Ltd?

The Market Cap of Sakar Healthcare Ltd is 585 Cr..

What is the current Stock Price of Sakar Healthcare Ltd as on 09 March 2025?

The current stock price of Sakar Healthcare Ltd as on 09 March 2025 is ₹267.

What is the High / Low of Sakar Healthcare Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Sakar Healthcare Ltd stocks is ₹408/213.

What is the Stock P/E of Sakar Healthcare Ltd?

The Stock P/E of Sakar Healthcare Ltd is 39.3.

What is the Book Value of Sakar Healthcare Ltd?

The Book Value of Sakar Healthcare Ltd is 123.

What is the Dividend Yield of Sakar Healthcare Ltd?

The Dividend Yield of Sakar Healthcare Ltd is 0.00 %.

What is the ROCE of Sakar Healthcare Ltd?

The ROCE of Sakar Healthcare Ltd is 7.31 %.

What is the ROE of Sakar Healthcare Ltd?

The ROE of Sakar Healthcare Ltd is 5.28 %.

What is the Face Value of Sakar Healthcare Ltd?

The Face Value of Sakar Healthcare Ltd is 10.0.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Sakar Healthcare Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE